A case of pulmonary metastasis of giant cell tumor of bone presenting as pulmonary arteriovenous malformation

Autor: Chang Dong Yeo, Sang Young Roh, Ok Ran Shin, Won Jong Bahk, Kwan Hyoung Kim, Jin Woo Kim

Publikováno v: Journal of the Formosan Medical Association, Vol 114, Iss 4, Pp 369-372 (2015)

Although giant-cell tumor (GCT) of the bone was originally classified as a benign tumor, metastasis has been reported. The radiographic features usually comprise parenchymal solitary or multiple nodules that are round-to-oval nodular opacities of hom

Externí odkaz: https://doaj.org/article/38af1ba203b6425ca0fc68b6e2e96c76

A Randomized Phase III Study of Patients With Advanced Gastric Adenocarcinoma Without Progression After Six Cycles of XELOX (Capecitabine Plus Oxaliplatin) Followed by Capecitabine Maintenance or Clinical Observation.

Autor: Guk Jin Lee, Hyunho Kim, Sung Shim Cho, Hyung Soon Park, Ho Jung An, In Sook Woo, Jae Ho Byun, Ji Hyung Hong, Yoon Ho Ko, Der Sheng Sun, Hye Sung Won, Jong Youl Jin, Ji Chan Park, In-Ho Kim, Sang Young Roh, Byoung Yong Shim

Publikováno v: Journal of Gastric Cancer; Apr2023, Vol. 23 Issue 2, p315-327, 13p

A Randomized Study of Patients with Advanced Gastric Adenocarcinoma Not Progressed After Six Cycles of XELOX (Capecitabine Plus Oxaliplatin) Followed by Capecitabine Maintenance or Clinical Observation

Autor: Guk Jin Lee, Hyunho Kim, Sung Shim Cho, Hyung Soon Park, Ho Jung An, In Sook Woo, Jae Ho Byun, Ji Hyung Hong, Yoon Ho Ko, Der Sheng Sun, Hye Sung Won, Jong Youl Jin, Ji Chan Park, In-Ho Kim, Sang Young Roh, Byoung Yong Shim

Background Oxaliplatin as part of XELOX regimen has a more favorable toxicity profile than cisplatin for patients with advanced gastric cancer (GC). However, oxaliplatin can induce sensory neuropathy, a cumulative, dose-related toxicity. Thus, capeci

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a2f9176dcdd45ccdbd0845f94a3af62d
https://doi.org/10.21203/rs.3.rs-1076759/v1

The neutrophil-to-lymphocyte ratio prechemotherapy and postchemotherapy as a prognostic marker in metastatic gastric cancer

Autor: Inho Kim, Sang Mi Ro, Sang Young Roh, Ji Hyun Yang, Joon Won Jeong, Jieun Lee, Hyunho Kim

Publikováno v: The Korean Journal of Internal Medicine

Background/Aims Markers of inflammation have been associated with outcomes in various cancers. The purpose of this study was to evaluate whether systemic inf lammatory markers and their f luctuations can predict survival and chemotherapy response in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::efe450acbfc4c55b42ed90e62bc69595
https://doi.org/10.3904/kjim.2016.293

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Autor: Kohei Shitara, Mustafa Özgüroğlu, Yung-Jue Bang, Maria Di Bartolomeo, Mario Mandalà, Min-Hee Ryu, Lorenzo Fornaro, Tomasz Olesiński, Christian Caglevic, Hyun C Chung, Kei Muro, Eray Goekkurt, Wasat Mansoor, Raymond S McDermott, Einat Shacham-Shmueli, Xinqun Chen, Carlos Mayo, S Peter Kang, Atsushi Ohtsu, Charles S Fuchs, Guillermo Lerzo, Juan Manuel O'Connor, Guillermo Ariel Mendez, James Lynam, Niall Tebbutt, Mark Wong, Andrew Strickland, Chris Karapetis, David Goldstein, Paul Vasey, Jean-Luc Van Laethem, Eric Van Cutsem, Scott Berry, Mark Vincent, Bettina Muller, Felipe Rey, Angela Zambrano, Joaquin Guerra, Merete Krogh, Lene Baeksgaard, Mette Yilmaz, Anneli Elme, Andrus Magi, Paivi Auvinen, Tuomo Alanko, Markus Moehler, Volker Kunzmann, Thomas Seufferlein, Peter Thuss-Patience, Thomas Hoehler, Georg Haag, Salah-Eddin Al-Batran, Hugo Castro, Karla Lopez, Mynor Aguilar Vasquez, Mario Sandoval, Ka On Lam, Sinead Cuffe, Cathy Kelly, Ravit Geva, Ayala Hubert, Alex Beny, Baruch Brenner, Aprile Giuseppe, Alfredo Falcone, Evaristo Maiello, Rodolfo Passalacqua, Vincenzo Montesarchio, Hiroki Hara, Keisho Chin, Tomohiro Nishina, Yoshito Komatsu, Nozumo Machida, Shuichi Hironaka, Taroh Satoh, Takao Tamura, Naotaoshi Sugimoto, Haruhiko Cho, Yashushi Omuro, Ken Kato, Masahiro Goto, Ichinosuke Hyodo, Kazuhiro Yoshida, Hideo Baba, Taito Esaki, Junji Furuse, Wan Zamaniah Wan Mohammed, Carlos Hernandez Hernandez, Juan Casas Garcia, Adriana Dominguez Andrade, Katriona Clarke, Geir Hjortland, Nils Glenjen, Tomasz Kubiatowski, Jassem Jacek, Marek Wojtukiewicz, Sergey Lazarev, Yuri Lancukhay, Sergey Afanasayev, Vladimir Moiseyenko, Vladimir Kostorov, Svetlana Protsenko, Vadim Shirinkin, Dina Sakaeva, Natalia Fadeeva, Wei Peng Yong, Chau Hsien Matthew Ng, Barbara Robertson, Bernardo Rapaport, Graham Cohen, Lydia Dreosti, Paul Ruff, Conrad Jacobs, Gregory Landers, Waldemar Szpak, Sang-Young Roh, Jeeyun Lee, Yeul Hong Kim, Hyun Cheol Chung, Maria Alsina Maqueda, Federico Longo Munoz, Andres Cervantes Aguilar, Enrique Aranda Aguilar, Pilar Garcia Alfonso, Fernando Rivera, Jaime Feliu Batle, Roberto Pazo Cid, Kun-Huei Yeh, Jen-Shi Chen, Yee Chao, Chia-Jui Yen, Oguz Kara, Suayib Yalcin, Daniel Hochhauser, Ian Chau, Al Benson, Veena Shankaran, Walid Shaib, Philip Philip, Vivek Sharma, Robert Siegel, Weijing Sun, Zev Wainberg, Ben George, Andrea Bullock, Samuel Myrick, Josephine Faruol, Richard Siegel, Timothy Larson, Carlos Becerra, Suresh Ratnam, Donald A. Richards, Stephen L. Riche

Publikováno v: The Lancet. 392:123-133

Summary Background Patients with advanced gastric or gastro-oesophageal junction cancer that progresses on chemotherapy have poor outcomes. We compared pembrolizumab with paclitaxel in patients with advanced gastric or gastro-oesophageal junction can

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88bba2ed478ffd93b7a80cdb96e7ab7b
https://doi.org/10.1016/s0140-6736(18)31257-1